Literature DB >> 23312902

Antigen-coated poly α-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinations.

Caitlin D Lemke1, Sean M Geary, Vijaya B Joshi, Aliasger K Salem.   

Abstract

Adenoviruses show promising potential as vectors for cancer vaccines, however, their high immunogenicity can be problematic when it comes to homologous prime-boost strategies. In the studies presented here we show that heterologous prime-boost vaccinations involving ovalbumin (OVA)-antigen-coated microparticles as a prime, and adenovirus encoding OVA (AdOVA) as a boost, were equally as effective as homologous AdOVA prime-boosts at generating OVA-specific CD8(+) T-cell responses, which translated into effective tumor protection. OVA-coated biodegradable poly α-hydroxy acid-based microparticles of varying chemistries, when used as primes in heterologous prime-boost vaccinations, were comparable in terms of promoting OVA-specific CD8(+) T cells as well as providing protection against subsequent tumor challenge. These findings auger well for using poly α-hydroxy acid-based microparticles in prime-boost viral vaccination strategies geared toward the safer, and potentially more efficient, generation of anti-tumor immunity.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23312902      PMCID: PMC3557532          DOI: 10.1016/j.biomaterials.2012.12.030

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  43 in total

1.  Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma.

Authors:  Robin Goforth; Aliasger K Salem; Xiaoyan Zhu; Suzanne Miles; Xue-Qing Zhang; John H Lee; Anthony D Sandler
Journal:  Cancer Immunol Immunother       Date:  2008-08-22       Impact factor: 6.968

2.  Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer.

Authors:  David M Lubaroff; Dev Karan; Michael P Andrews; Anna Acosta; Chadi Abouassaly; Madeva Sharma; Arthur M Krieg
Journal:  Vaccine       Date:  2006-05-03       Impact factor: 3.641

Review 3.  Generation of tumor-specific T-cell therapies.

Authors:  Emma Morris; Dan Hart; Liquan Gao; Aristotle Tsallios; Shao-An Xue; Hans Stauss
Journal:  Blood Rev       Date:  2005-06-22       Impact factor: 8.250

4.  Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.

Authors:  David M Lubaroff; Badrinath R Konety; Brian Link; Jack Gerstbrein; Tammy Madsen; Mary Shannon; Jeanne Howard; Jennifer Paisley; Diana Boeglin; Timothy L Ratliff; Richard D Williams
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531

5.  Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.

Authors:  James W Hodge; Jack Higgins; Jeffrey Schlom
Journal:  Vaccine       Date:  2009-05-29       Impact factor: 3.641

6.  Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo.

Authors:  Janjira Intra; Aliasger K Salem
Journal:  J Control Release       Date:  2008-04-24       Impact factor: 9.776

7.  Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.

Authors:  Maria R Sorensen; Peter J Holst; Hanspeter Pircher; Jan P Christensen; Allan R Thomsen
Journal:  Eur J Immunol       Date:  2009-10       Impact factor: 5.532

8.  Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.

Authors:  Dev Karan; Arthur M Krieg; David M Lubaroff
Journal:  Int J Cancer       Date:  2007-10-01       Impact factor: 7.396

9.  Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles.

Authors:  Xue-Qing Zhang; Christopher E Dahle; Nicki K Baman; Nathan Rich; George J Weiner; Aliasger K Salem
Journal:  J Immunother       Date:  2007 Jul-Aug       Impact factor: 4.456

Review 10.  CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.

Authors:  David M Lubaroff; Dev Karan
Journal:  Adv Drug Deliv Rev       Date:  2009-01-07       Impact factor: 15.470

View more
  4 in total

1.  Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.

Authors:  Sean M Geary; Qiaohong Hu; Vijaya B Joshi; Ned B Bowden; Aliasger K Salem
Journal:  J Control Release       Date:  2015-09-08       Impact factor: 9.776

Review 2.  Improving the clinical impact of biomaterials in cancer immunotherapy.

Authors:  Joshua M Gammon; Neil M Dold; Christopher M Jewell
Journal:  Oncotarget       Date:  2016-03-29

Review 3.  Nanocarrier-based immunotherapy in cancer management and research.

Authors:  Manu Smriti Singh; Sangeeta Bhaskar
Journal:  Immunotargets Ther       Date:  2014-06-26

Review 4.  Applying biodegradable particles to enhance cancer vaccine efficacy.

Authors:  Kawther K Ahmed; Sean M Geary; Aliasger K Salem
Journal:  Immunol Res       Date:  2014-08       Impact factor: 4.505

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.